Q-omics provides the consensus-scored RBFOX2 profile across patient tissues and cancer cell-line models. RBFOX2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RBFOX2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RBFOX2 RNA expression shows 20,450 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where RBFOX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBFOX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBFOX2 survival associations across molecular data types. RBFOX2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBFOX2 RNA expression–survival associations across cancer types. High RBFOX2 expression shows unfavorable associations in ACC, UVM and HNSC, but favorable associations in UCS, ESCA and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RBFOX2 RNA expression.
This table summarizes RBFOX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBFOX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBFOX2 shows lower tumor expression in THCA, UCEC and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher RBFOX2 RNA expression in tumor versus normal tissue (log2 FC = +1.196, t-test p < 0.001).
This table shows molecular features associated with RBFOX2 in patient tissues and cancer cell lines. In patient samples, RBFOX2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBFOX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
